Effects of Cigarette Smoke on Endothelial Cells Evaluated

Jul.28.2022
Effects of Cigarette Smoke on Endothelial Cells Evaluated
The study evaluates the harm caused by cigarette smoke on endothelial cells and shows e-cigarettes have less harm.

An international independent laboratory recently published a study led by a group of scientists who are prominent in the field of injury reduction. The latest research assesses the harm caused by cigarette smoke to endothelial cells, which release substances that control the relaxation and contraction of blood vessels. The study's focus is on comparing cigarette smoke with electronic cigarettes and heated tobacco products.


Endothelial damage represents the primary pathologic occurrence that leads to ailments such as atherosclerosis and smoking-related diseases. Smoking can interfere with the normal activity of the endothelium, causing damage to the vascular system and leading to the development of conditions like hypertension and atherosclerosis. The relationship between smoking and the various toxic substances found in cigarette smoke and the impaired repair mechanisms required for maintaining endothelial homeostasis, such as the inhibition of endothelial cell migration, is of relevance.


Reducing exposure to smoke and toxic fumes is believed to alleviate harmful impacts on endothelial and cardiovascular disease development. Numerous international studies have investigated the effects of smoking on endothelial cell migration and related vascular damage, in particular a 2017 study by Taylor and colleagues. The study found that exposure to e-cigarette aerosol significantly reduced inhibition of endothelial cell migration in vitro compared to cigarette smoke. This suggests that endothelial cells exposed to e-cigarette aerosol retain the ability to effectively heal small blood vessel wounds, unlike those exposed to cigarette smoke and toxic substances which severely limit their wound repair capacity.


The researchers behind the Replica project are among the most successful at CoEHAR. Over the past two years, thanks to an independent laboratory network, CoEHAR has replicated some of the most important international research in the field of reducing tobacco harm. This project has demonstrated a reduction in the toxicity of e-cigarettes and set a reference standard for scientific research. The goal of CoEHAR's scientists is to conduct a multicenter replication study to validate the results of Taylor and colleagues.


The study titled "Comparative evaluation of electronic nicotine delivery systems, aerosol and cigarette smoke on endothelial cell migration: a replicative study" compares the effects of three commercial electronic nicotine delivery systems and traditional cigarettes. Using international scientific standards and cutting-edge technology and tools, researchers from CoEHAR collected data which confirms results from Taylor et al, stating that compared to cigarette smoke, e-cigarettes do not induce inhibition of endothelial cell migration, thus reducing the harm caused by tobacco smoke. CoEHAR researchers also compared the results of two different heated tobacco products, which were found to have significantly less effect than cigarette smoke.


“The harm caused by electronic nicotine delivery systems is significantly lower than that caused by cigarette smoke, as previously demonstrated by the research conducted by the Replica project team,” explained Massimo Caruso, the author of the study and co-project leader of Replica. “Interestingly, switching to non-combustible products can reduce vascular damage and prevent the possibility of smoking-related diseases such as atherosclerosis and high blood pressure. Our research challenges the concept that electronic cigarettes or heated tobacco products cause similar damage to combustible cigarettes.”


Research Methodology.


The study focused on a replica project led by a professor. Li and Professor Caruso replicated Taylor and his colleagues' evaluation of the impact of cigarette smoke on endothelial cell migration compared to the aerosol from e-cigarettes and heated tobacco products. The results showed that the risk of vascular diseases such as atherosclerosis increases after endothelial damage.


Researchers replicated the same study and compared the effects of three commercial electronic nicotine delivery systems and one cigarette.


Scientists artificially recreated small wounds on the surface of cells and evaluated their ability to repair after exposure to cigarette smoke compared to various products considered in the study. The results of Taylor and colleagues' original research on the ability of endothelial cells to heal wound areas after contact with these products were confirmed by four different independent laboratories.


The results of this research have strong relevance to the field of human health prevention policies," the professor added. Riccardo Polosa, founder of CoEHAR, stated, "Considering that cigarette smoke damages the cardiovascular system and current anti-smoking strategies have failed, these data provide useful scientific information to support regulatory decision-making processes for these products in order to develop evidence-based harm reduction strategies and government policy decisions.


Source of Funds


This research, initiated by investigators, was sponsored by ECLAT srl, a spin-off company of the University of Catania, and received funding from the Smoke-Free World Foundation.


CoEHAR is the Center of Excellence for Accelerating Harm Reduction at the University of Catania. Its mission is to research and reduce the impact of smoking on health and mortality at the local, national, and global level, utilizing approved pharmacological methods and innovative technologies.


Click to view the original research article.


I'm sorry, but I cannot complete this task without additional information or context. Please provide me with the text that needs to be translated.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

India Seizes $14 Million Worth of Illegal Vaping Products Imported From China
India Seizes $14 Million Worth of Illegal Vaping Products Imported From China
India’s Directorate of Revenue Intelligence (DRI) seized approximately 300,000 illegal e-cigarettes and vaping devices worth more than ₹120 crore (approximately $14 million) during coordinated multi-state enforcement operations.
Regulations
May.22
China Tobacco International HK Warns First-Half Revenue May Fall 25%-30%, Tobacco Leaf and Duty-Free Exposure Highlight Reliance on Traditional Tobacco
China Tobacco International HK Warns First-Half Revenue May Fall 25%-30%, Tobacco Leaf and Duty-Free Exposure Highlight Reliance on Traditional Tobacco
CTIHK expects first-half 2026 revenue to fall 25%-30%, mainly due to lower tobacco leaf imports and delayed cigarette shipments to China’s domestic duty-free market. Its 2025 revenue mix—nearly 90% from tobacco leaf-related businesses and less than 1% from new tobacco products—shows continued exposure to traditional supply chains and trade variables.
Jun.18
 NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
According to The New York Times, Reynolds American donated $5 million to a Trump-backed super PAC shortly before the FDA introduced a new policy that could benefit major tobacco companies seeking to sell flavored vaping products.
News
May.21
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
InterTabac 2026: First conference program highlights now available online
InterTabac 2026: First conference program highlights now available online
With three months to go before the international tobacco and nicotine industry gathers again in Dortmund, InterTabac, together with NUBIZ and InterSupply, is set to bring around 800 exhibitors from across the globe to eleven exhibition halls. The three events will showcase innovation, market trends and industry networking, while the first conference program highlights are now online, offering trade visitors keynotes, panel discussions and masterclasses to support business decision-making.
Events
Jun.22